#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Leiomyosarcoma metastatic Rett syndrome Familial dilated cardiomyopathy Haemolytic uraemic syndrome Hypertriglyceridaemia Acute myeloid leukaemia Richter's syndrome Cardiac failure acute Drug eruption Chronic graft versus host disease in intestine Glycogen storage disease type V Liposarcoma Ventricular tachycardia Osteosarcoma Depression More trials…

    Learn about Rare Diseases

    Gastrointestinal stromal tumour – Treatment Nephroblastoma Leiomyosarcoma metastatic – Diagnostics Mastocytosis – Life with Disease Systemic mastocytosis Mucopolysaccharidosis III Medulloblastoma – Trials in Disease Extranodal marginal zone B-cell lymphoma (MALT type) – Basic Information Leiomyosarcoma – Treatment Haemolytic uraemic syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    MB-HUCART19.1 Bi 1291583 Istradefylline Vinorelbine Nemtabrutinib Sumatriptan Succinate Betula Verrucosa (108) Salbutamol Sulfate Ondansetron Hydrochloride RPTR-1-201 GXV813 Taldefgrobep Alfa Rbl027.2 CANNABINOL OLVEREMBATINIB Ivospemin Padeliporfin H2-Receptor Antagonist Ibuprofen Lysine Phenol More therapies…

    Learn about Your Condition

    Peritoneal abscess Adenocarcinoma Ependymoma malignant Vulvovaginal candidiasis Complicated appendicitis Intellectual disability Pertussis Oropharyngeal cancer recurrent Netherton's syndrome Traumatic pain Conjunctivitis allergic Fragile X syndrome Hypertension Eructation Asplenia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Acute myeloid leukaemia refractory

  • Study of S227928 Alone and with Venetoclax for Patients with Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia recurrent
    • Acute myeloid leukaemia refractory
    • Chronic myelomonocytic leukaemia
    Investigated Drugs:
    • Rasburicase
    • S227928
    • Allopurinol
    Finland France Germany
  • Study of SAR443579 Infusion for Adults and Children with Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, HR-MDS, or BPDCN

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia refractory
    • Blastic plasmacytoid dendritic cell neoplasia
    • Myelodysplastic syndrome
    Investigated Drugs:
    • Chlorphenamine Maleate
    • Dextromethorphan Hydrobromide
    • Sar-443579
    France The Netherlands
Previous Page
1 2

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.


European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!